glp-1 therapies WHO Endorses GLP‑1 Therapy Obesity Care: Implications for Diabetes Providers The GLP-1 revolution: What UAB

doi: 10.1016/j.jff.2017.02.006 97

Americans Face An Affordability Crisis By restricting compounders, the FDA has transformed a production shortage into an affordability shortage

Available from: Brittany V B Johnson 1 , Mary Milstead 1 , Rachel Kreider 1 , Rachel Jones 1 Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review

Your body makes enzymes, but GLP-1s change how fast food moves through your system

Common maintenance approaches include staying at the dose where you stabilized (often 1.0 to 1.7 mg), reducing by one dose level from your peak (e.g., from 2.4 mg to 1.7 mg), or finding the minimum dose that prevents weight regain while minimizing side effects

Neuroprotective Properties: Some research suggests that BPC-157 peptide therapy may help protect brain cells and nerves, potentially supporting recovery from brain injuries and neurodegenerative conditions